Iterum Therapeutics plc

NasdaqCM ITRM

Iterum Therapeutics plc Shares (Diluted, Weighted) for the year ending December 31, 2023: 12,962,362

Iterum Therapeutics plc Shares (Diluted, Weighted) is 12,962,362 for the year ending December 31, 2023, a 5.93% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Iterum Therapeutics plc Shares (Diluted, Weighted) for the year ending December 31, 2022 was 12,236,607, a -92.51% change year over year.
Iterum Therapeutics plc Shares (Diluted, Weighted) for the year ending December 31, 2021 was 163,367,681, a 580.42% change year over year.
Iterum Therapeutics plc Shares (Diluted, Weighted) for the year ending December 31, 2020 was 24,009,818, a 65.38% change year over year.
Iterum Therapeutics plc Shares (Diluted, Weighted) for the year ending December 31, 2019 was 14,518,036, a 2,393.34% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: ITRM

Iterum Therapeutics plc

CEO	Mr. Corey N. Fishman
IPO Date	May 25, 2018
Location	Ireland
Headquarters	Fitzwilliam Court
Employees	14
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years